The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Donor-Specific Antibodies in Kidney Transplant Recipients
Open accessAbstract
Donor-specific antibodies have become an established biomarker predicting antibody-mediated rejection. Antibody-mediated rejection is the leading cause of graft loss after kidney transplant. There are several phenotypes of antibody-mediated rejection along post-transplant course that are determined by the timing and extent of humoral response and the various characteristics of donor-specific antibodies, such as antigen classes, specificity, antibody strength, IgG subclasses, and complement binding capacity. Preformed donor-specific antibodies in sensitized patients can trigger hyperacute rejection, accelerated acute rejection, and early acute antibody-mediated rejection. De novo donor-specific antibodies are associated with late acute antibody-mediated rejection, chronic antibody-mediated rejection, and transplant glomerulopathy. The pathogeneses of antibody-mediated rejection include not only complement-dependent cytotoxicity, but also complement-independent pathways of antibody-mediated cellular cytotoxicity and direct endothelial activation and proliferation. The novel assay for complement binding capacity has improved our ability to predict antibody-mediated rejection phenotypes. C1q binding donor-specific antibodies are closely associated with acute antibody-mediated rejection, more severe graft injuries, and early graft failure, whereas C1q nonbinding donor-specific antibodies correlate with subclinical or chronic antibody-mediated rejection and late graft loss. IgG subclasses have various abilities to activate complement and recruit effector cells through the Fc receptor. Complement binding IgG3 donor-specific antibodies are frequently associated with acute antibody-mediated rejection and severe graft injury, whereas noncomplement binding IgG4 donor-specific antibodies are more correlated with subclinical or chronic antibody-mediated rejection and transplant glomerulopathy. Our in-depth knowledge of complex characteristics of donor-specific antibodies can stratify the patient’s immunologic risk, can predict distinct phenotypes of antibody-mediated rejection, and hopefully, will guide our clinical practice to improve the transplant outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sellarés, J., de Freitas, D. G., Mengel, M., Reeve, J., Einecke, G., Sis, B., Hidalgo, L. G., Famulski, K., Matas, A., & Halloran, P. F. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03840.x · Cited by 1,590
Haas, M., Sis, B., Racusen, L. C., Solez, K., Glotz, D., Colvin, R. B., Castro, M. C. R., David, D. S. R., David-Neto, E., Bagnasco, S. M., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12590 · Cited by 1,350
Wiebe, C., Gibson, I. W., Blydt-Hansen, T. D., Karpinski, M., Ho, J., Storsley, L. J., Goldberg, A., Birk, P. E., Rush, D. N., & Nickerson, P. W. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04013.x · Cited by 950
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
Dragun, D., Müller, D. N., Bräsen, J. H., Fritsche, L., Nieminen-Kelhä, M., Dechend, R., Kintscher, U., Rudolph, B., Hoebeke, J., Eckert, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa035717 · Cited by 868
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
Loupy, A., Lefaucheur, C., Vernerey, D., Prugger, C., van Huyen, J.-P. D., Mooney, N., Suberbielle, C., Frémeaux-Bacchi, V., Méjean, A., Desgrandchamps, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302506 · Cited by 852
Stegall, M. D., Diwan, T., Raghavaiah, S., Cornell, L. D., Burns, J., Dean, P. G., Cosio, F. G., Gandhi, M. J., Kremers, W., & Gloor, J. M. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03757.x · Cited by 577
Antibodies against MICA Antigens and Kidney-Transplant Rejection
Zou, Y., Stastny, P., Süsal, C., Döhler, B., & Opelz, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067160 · Cited by 454
Hidalgo, L. G., Sis, B., Sellares, J., Campbell, P. M., Mengel, M., Einecke, G., Chang, J., & Halloran, P. F. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03201.x · Cited by 428
Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
Everly, M. J., Everly, J. J., Susskind, B., Brailey, P., Arend, L. J., Alloway, R. R., Roy-Chaudhury, P., Govil, A., Mogilishetty, G., Rike, A. H., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e318190af83 · Cited by 392
Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts
Everly, M. J., Rebellato, L. M., Haisch, C. E., Ozawa, M., Parker, K., Briley, K. P., Catrou, P. G., Bolin, P., Kendrick, W. T., Kendrick, S. A., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e31827d62e3 · Cited by 385
Cited by
Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage
Franzin, R., Stasi, A., Fiorentino, M., Stallone, G., Cantaluppi, V., Gesualdo, L., & Castellano, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00734 · Cited by 93
Metadata
- Authors
- Zhang, R.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2017-04-26
- Volume
- 13
- Issue
- 1
- Pages
- 182-192
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- OpenAlex
- W2609351880
- Cited by
- 290
- References
- 44
- FWCI
- 17.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Donor-Specific Antibodies in Kidney Transplant Recipients. https://app.cochat.ai/papers/10.2215/cjn.00700117
- The paper
- Zhang, R. (2018). Donor-Specific Antibodies in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.00700117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.